Xtandi® (enzalutamide)

Humana

Pharmacy Coverage Policy

Effective Date: January 01, 2019
Revision Date: March 23, 2022
Review Date: March 16, 2022
Line of Business: Medicare, Commercial, HUM Medicaid
Policy Type: Prior Authorization

For the Humana Medicaid line of business, the following state applies: South Carolina. For other state-managed Medicaid plans, please refer to the state's Medicaid pharmacy site for pharmacy coverage policies.

Disclaimer

State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. See the CMS website at http://www.cms.hhs.gov/. The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically.

Description

Xtandi (enzalutamide) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Xtandi (enzalutamide) has been shown to competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and interaction with DNA.

Xtandi (enzalutamide) is indicated for the treatment of patients with (1) metastatic castration-resistant prostate cancer; (2) non-metastatic castration-resistant prostate cancer; and (3) metastatic castration-sensitive prostate cancer.

Enzalutamide is available as Xtandi in 40 mg capsules or tablets and 80 mg tablets.

Coverage Determination

Please note the following regarding medically accepted indications:

All reasonable efforts have been made to ensure consideration of medically accepted indications in this policy. Medically accepted indications are defined by CMS as those uses of a covered Part D drug that are approved under the federal Food, Drug and Cosmetic Act, or the use of which is supported by one or more citations included or approved for inclusion in any of the compendia described in section 1927(g)(1)(B)(i) of

the Act. These compendia guide review of off-label and off-evidence prescribing and are subject to minimum evidence standards for each compendium. Currently, this review includes the following references when applicable and may be subject to change per CMS:

- American Hospital Formulary Service-Drug Information (AHFS-DI)
- National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
- Truven Health Analytics Micromedex DrugDEX
- Elsevier/Gold Standard Clinical Pharmacology
- Wolters Kluwer Lexi-Drugs

Xtandi (enzalutamide) will require prior authorization. This agent may be considered medically necessary when the following criteria are met:

Prostate Cancer (metastatic castration-resistant)

- The member has metastatic (stage IV) castration-resistant prostate cancer (CRPC)

Prostate Cancer (non-metastatic castration-resistant)

- The member has a diagnosis of non-metastatic castration-resistant prostate cancer **AND**
- The member will use Xtandi (enzalutamide) in combination with androgen deprivation therapy (e.g. previous bilateral orchiectomy or GnRH analog)

Prostate Cancer (metastatic castration-sensitive)

- The member has a diagnosis of metastatic castration-sensitive prostate cancer **AND**

- The member will use Xtandi (enzalutamide) in combination with androgen deprivation therapy (e.g. previous bilateral orchiectomy or GnRH analog)

Xtandi (enzalutamide) will be approved in six month durations or as determined through clinical review.

Coverage Limitations

Xtandi (enzalutamide) therapy is not considered medically necessary for members with the following concomitant conditions

- Concomitant use with Erleada (apalutamide), Zytiga (abiraterone acetate), Provenge (sipuleucel-T), Taxotere (docetaxel) or Jevtana (cabazitaxel) is not recommended at this time due to lack of evidence supporting safety and efficacy
- Members that have experienced disease progression while on Xtandi (enzalutamide)

- Experimental/Investigational Use – Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

Background

This is a prior authorization policy about Xtandi (enzalutamide).

The PROSPER trial supported expanded indication approval of Xtandi (enzalutamide) in the non-metastatic castration-resistant prostate cancer space. In this trial, patients were included if they were 18 years of age or older, had confirmed adenocarcinoma of the prostate that was castration-resistant. Patients had to have been receiving androgen-deprivation therapy with a gonadotropin releasing hormone agonist or antagonist or to have undergone bilateral orchiectomy. Patients also had to have a minimum of three rising PSA values at an interval of at least 1 week apart, a baseline PSA level of 2 ng per milliliter or greater, and a PSA doubling time of 10 months or less. Patients were excluded with previous or current evidence of metastatic disease. Patients with suspected brain metastases or active leptomeningeal disease or with a history of seizure or a condition that may confer a predisposition to seizure were excluded.

Pregnancy:
Xtandi (enzalutamide) can cause fetal harm when administered to a pregnant woman based on its mechanism of action. Xtandi (enzalutamide) is not indicated for use in women. Xtandi (enzalutamide) is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus and the potential risk for pregnancy loss.

Seizure Risk:
In clinical trials, 0.9% of patients treated with enzalutamide 160mg once daily experienced a seizure. Seizures occurred from 31 to 603 days after initiation of Xtandi (enzalutamide). Patients experiencing seizure were permanently discontinued from therapy and all seizures resolved. There is no clinical trial experience re-administering Xtandi (enzalutamide) to patients who experienced seizures. The safety of Xtandi (enzalutamide) in patients with predisposing factors for seizure is not known because these patients were excluded from the trial. Exclusion criteria included a history of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, brain arteriovenous malformation or the use of concomitant medications that may lower the seizure threshold. Because of the risk of seizure associated with Xtandi (enzalutamide) use, patients should be advised of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others

For specific recommendations on warnings and precautions, patient monitoring and on dose adjustments, omissions, and discontinuation, please refer to the current prescribing information.

Provider Claims Codes

For medically billed requests, please visit www.humana.com/PAL. Select applicable Preauthorization and Notification List(s) for medical and procedural coding information.

Medical Terms

Xtandi; enzalutamide; prostate cancer; pharmacy

References

Clinical Pharmacology [online database]. Tampa, FL: Gold Standard, Inc. URL: http://www.clinicalpharmacology.com. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.

Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically.

NCCN Drug and Biologics Compendium. Fort Washington, PA: National Comprehensive Cancer Network (NCCN); Updated periodically.

Xtandi Prescribing Information. Astellas Pharma Inc. Northbrook, IL. January 2022.